Asia-pacific Stem Cell Market Forecast 2022-2030

The Asia-Pacific stem cell market is predicted to register a CAGR of 9.16% over the forecasted years 2022 to 2030. Some of the top drivers strengthening the regional market's growth include substantial investments in medical research and healthcare facilities, increasing medical tourism in emerging countries like China and India, and collaborations between Asian governments, private enterprises, and international health agencies.

MARKET INSIGHTS

The Asia-Pacific stem cell market growth assessment includes the analysis of Vietnam, Australia & New Zealand, South Korea, China, Japan, India, Thailand, Indonesia, and Rest of Asia Pacific. Stem cell research, as well as regenerative medicine, are emerging fields in South Korea, with primary government support acquired through the National Center for Stem Cell and Regenerative Medicine. Established in 2010, the Korea Stem Cell Registry (KSCR) focuses on the improvement of the human embryonic stem cell line's credibility. By 2019, subsequently, several companies and research centers were established in the country.

In this regard, the National Stem Cell Bank of Korea was initiated with a core emphasis on pluripotent stem cell banking as well as the quality control and distribution of stem cells. Although bioethical issues restricted the growth of stem cell research in South Korea, in 2016, the Ministry of Health and Welfare offered conditional approval to Cha University, following which research based on somatic cell cloning embryos resumed. Hence, these factors are set to encourage the growth of the stem cell market in the Asia-Pacific during the forecast period.

COMPETITIVE INSIGHTS

Leading firms operating in the market are: Takara Holdings Inc, Becton, Dickinson and Company, Qiagen NV, etc.

Our report offerings include:

Explore key findings of the overall market

Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)

Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions

Market Segmentation caters to a thorough assessment of key segments with their market estimations

Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.

The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.

Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Product Code: 5141

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. SURGING DEMAND FOR STEM CELLS IN REGENERATIVE MEDICINE
- 3.1.2. GROWING R&D INVESTMENTS IN STEM CELL THERAPIES & RESEARCH
- 3.1.3. RISING AWARENESS ABOUT UMBILICAL CORD STEM CELLS
- 3.1.4. REDUCED RISK OF TISSUE REJECTION IN TRANSPLANTS
3.2. KEY RESTRAINTS
- 3.2.1. ABSENCE OF A WELL-DEFINED REGULATORY FRAMEWORK FOR STEM CELL THERAPY
- 3.2.2. HIGH COSTS ASSOCIATED WITH STEM CELL PROCEDURES
- 3.2.3. ETHICAL ISSUES AND SOCIAL COMPLEXITIES
- 3.2.4. LESS RESPONSIVENESS IN DEVELOPED ECONOMIES

4. KEY ANALYTICS

4.1. IMPACT OF COVID-19 ON STEM CELL MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
4.6. VALUE CHAIN ANALYSIS
4.7. KEY BUYING CRITERIA
- 4.7.1. PRICE
- 4.7.2. EFFICACY
- 4.7.3. APPLICATION AND EFFECTIVENESS
- 4.7.4. ACCURACY
4.8. REGULATORY FRAMEWORK

5. MARKET BY THERAPEUTIC APPLICATION

5.1. ORTHOPEDIC TREATMENTS
5.2. INJURIES & WOUNDS
5.3. ONCOLOGY DISORDERS
5.4. CARDIOVASCULAR DISORDERS
5.5. NEUROLOGICAL DISORDERS
5.6. DIABETES
5.7. OTHER THERAPEUTIC APPLICATIONS

6. MARKET BY PRODUCT

6.1. ADULT STEM CELL
- 6.1.1. HEMATOPOIETIC STEM CELL
- 6.1.2. NEURAL STEM CELL
- 6.1.3. UMBILICAL CORD STEM CELL
- 6.1.4. MESENCHYMAL STEM CELL
- 6.1.5. DENTAL STEM CELL
6.2. HUMAN EMBRYONIC STEM CELL
6.3. PLURIPOTENT
6.4. MOUSE/RAT NEURAL

7. MARKET BY TECHNOLOGY

7.1. CELL ACQUISITION
- 7.1.1. BONE MARROW HARVEST
- 7.1.2. UMBILICAL CORD
- 7.1.3. APHERESIS
7.2. CELL PRODUCTION
- 7.2.1. THERAPEUTIC CLONING
- 7.2.2. IN VITRO FERTILIZATION (IVF)
- 7.2.3. CELL CULTURE
- 7.2.4. ISOLATION
7.3. CRYOPRESERVATION
7.4. EXPANSION & SUB-CULTURE

8. MARKET BY APPLICATION

8.1. REGENERATIVE MEDICINE
8.2. DRUG DISCOVERY AND DEVELOPMENT

9. MARKET BY TREATMENT TYPE

9.1. ALLOGENEIC STEM CELL THERAPY
9.2. AUTOLOGIC STEM CELL THERAPY
9.3. SYNGENEIC STEM CELL THERAPY

10. GEOGRAPHICAL ANALYSIS

10.1. ASIA-PACIFIC
- 10.1.1. MARKET ESTIMATES & SIZES
- 10.1.2. KEY GROWTH ENABLERS
- 10.1.3. KEY CHALLENGES
- 10.1.4. KEY PLAYERS
- 10.1.5. COUNTRY ANALYSIS
  - 10.1.5.1. CHINA
  - 10.1.5.2. JAPAN
  - 10.1.5.3. INDIA
  - 10.1.5.4. AUSTRALIA & NEW ZEALAND
  - 10.1.5.5. SOUTH KOREA
  - 10.1.5.6. THAILAND
  - 10.1.5.7. INDONESIA
  - 10.1.5.8. VIETNAM
  - 10.1.5.9. REST OF ASIA-PACIFIC

11. COMPETITIVE LANDSCAPE

11.1. KEY STRATEGIC DEVELOPMENTS
- 11.1.1. ACQUISITIONS
- 11.1.2. PARTNERSHIPS
11.2. COMPANY PROFILES
- 11.2.1. ALLCELLS LLC
- 11.2.2. BECTON, DICKINSON AND COMPANY (BD)
- 11.2.3. CORNING INC
- 11.2.4. LOREM CYTORI INC
- 11.2.5. GE HEALTHCARE
- 11.2.6. INTERNATIONAL STEM CELL CORPORATION
- 11.2.7. MERCK KGAA (SIGMA ALDRICH)
- 11.2.8. MILTENYI BIOTEC
- 11.2.9. PLURI INC
- 11.2.10. QIAGEN
- 11.2.11. SMITH+NEPHEW PLC
- 11.2.12. STEMCELL TECHNOLOGIES INC
- 11.2.13. STRYKER CORPORATION
- 11.2.14. TAKARA HOLDINGS INC
- 11.2.15. THERMO FISHER SCIENTIFIC INC